Clinical Trial Update: Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). [Phase 1]

View source ↗

Summary

A Phase 1 trial comparing a once-daily 900 mg dose of TETA 4HCl to Cuprior (trientine) in Wilson's disease has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wilson Disease

Drugs mentioned

• Cuprior (trientine)
• TETA 4HCl (triethylenetetramine tetrahydrochloride)

Snippet

Sponsor: Orphalan | Conditions: Wilson's Disease | Phase 1 | Status: COMPLETED | Results posted: 2025-08-15